{"prompt": "['Trelagliptin-4002', 'Page 28 of 66', 'Version 2.0', 'July 5,10', '7.3', 'Prohibited concomitant drugs and permitted concomitant drugs', 'The use of diabetic medications other than allocated oral glucose-lowering medication will', 'be prohibited during from the start of the screening period (Week -4) until the end of the', 'treatment period (Week 12).', '<Rationale of prohibited concomitant drugs>', 'It was designed due to potential influences on the assessment of this clinical study.', '7.4', 'Study subject management', 'The principal investigator and investigator shall instruct the research subject the items below.', '(1) Give instructions to take allocated oral hypoglycemic drug as directed.', '(2)', 'If hypoglycemia symptom (hunger abnormal, feeling of weakness, trembling of hands and', 'fingers, cold sweat, palpitations, etc.) is observed, take glucose or sucrose (sugar), and if it does', 'not improve give instructions to visit promptly.', '(3)', 'On visit days for planned laboratory tests, give instructions not to take oral hypoglycemic drug', 'scheduled to be taken on that day. Further, at each visit, have the research subject report if drug', 'has been taken or not the day before, and on the day of visit.', '(4) On visit days for planned laboratory tests, give instructions for fasting > 10 hours before visit', '(excluding start of observation period).', '(5) For research subjects of childbearing potential, give instructions to use adequate contraception.', 'If pregnancy is discovered, have the research subject report promptly, and discontinue the', 'research immediately.', '(6)', 'The principal investigator and investigator shall instruct the research subject to adhere to', 'instructed prohibited concomitant drugs. When drugs are taken other than the drugs prescribed', 'by the principal investigator and investigator, have the research subject report its content.', '(7) Regarding subjective symptoms/objective findings, have the research subject report at visit the', 'necessary items from its contents, onset date, degree, outcome and date of outcome.', '7.5', 'Criteria for discontinuation or withdrawal of a study subject', 'The principal investigator or investigator shall record the main reason for discontinuation of protocol', 'treatment on the case report form (CRF) according to the classification described below. Refer to', 'Section 9.1.15 for study subjects who withdraw from the study before randomization.', '1. Adverse events', 'When the study subject had an adverse event that requires withdrawal of the study subject from', 'the study because continued participation in the study would impose an unacceptable risk to the', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 29 of 66', 'Version 2.0', 'July 5,10', \"study subject's health, or when the study subject is unwilling to continue study participation\", 'because of the adverse event.', '2. Major protocol deviation', 'When it is discovered after randomization that a study subject does not meet the eligibility', 'criteria or is not adhering to the protocol, and continued participation in the study would impose', \"an unacceptable risk to the study subject's health.\", '3. Lost to follow-up', 'When the study subject failed to make visits and could not be contacted despite the attempts to', 'contact the study subject.', '4. Voluntary termination', 'When the study subject wishes to withdraw from the study. The reason for discontinuation shall', 'be obtained to the extent possible.', '5.', 'Study termination', 'When the sponsor or a committee such as the Ethical Review Board or regulatory authority has', 'decided to terminate the study. Refer to Section 6.3.1 for details.', '6. Pregnancy', 'When a female study subject was found to be pregnant.', 'Note: The study subject must discontinue the study immediately after she was found to be', 'pregnant. Refer to Section 9.1.13 for the procedures.', '7. Lack of efficacy', 'When efficacy of the study drug is not evident and continuation of the study may pose an', 'unacceptable risk to the study subjects in the opinion of the principal investigator or', 'investigator.', '8. Others', 'When the principal investigator or investigator determined to terminate the study for other', 'reasons.', 'The specific reasons should be recorded on the CRF.', '7.6', 'Procedures for discontinuation of individual study subjects', \"The principal investigator or investigator shall terminate a study subject's study participation when\", 'the study subject meets the criteria described in Section 7.5. Individual study subjects may', 'discontinue their study participation without giving a reason at any time during the study. Should a', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}